Morgan Stanley’s Celyad Oncology SA American Depositary Shares CYAD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-100
| Closed | -$96 | – | 7792 |
|
|
2023
Q1 | $96 | Sell |
100
-18,200
| -99% | -$20.6K | ﹤0.01% | 7576 |
|
|
2022
Q4 | $9.02K | Sell |
18,300
-600
| -3% | -$608 | ﹤0.01% | 6980 |
|
|
2022
Q3 | $26K | Sell |
18,900
-1,000
| -5% | -$1.84K | ﹤0.01% | 6682 |
|
|
2022
Q2 | $34K | Sell |
19,900
-100
| -0.5% | -$200 | ﹤0.01% | 6791 |
|
|
2022
Q1 | $49K | Sell |
20,000
-3,958
| -17% | -$12.1K | ﹤0.01% | 6718 |
|
|
2021
Q4 | $88K | Sell |
23,958
-862
| -3% | -$3.62K | ﹤0.01% | 6517 |
|
|
2021
Q3 | $102K | Buy |
24,820
+300
| +1% | +$1.31K | ﹤0.01% | 6368 |
|
|
2021
Q2 | $129K | Buy |
24,520
+900
| +4% | +$5.38K | ﹤0.01% | 6231 |
|
|
2021
Q1 | $166K | Sell |
23,620
-6,496
| -22% | -$51.1K | ﹤0.01% | 5766 |
|
|
2020
Q4 | $235K | Sell |
30,116
-1,642
| -5% | -$14.1K | ﹤0.01% | 5514 |
|
|
2020
Q3 | $314K | Sell |
31,758
-267
| -0.8% | -$2.69K | ﹤0.01% | 4881 |
|
|
2020
Q2 | $343K | Sell |
32,025
-7,748
| -19% | -$75.6K | ﹤0.01% | 4798 |
|
|
2020
Q1 | $296K | Buy |
39,773
+1,915
| +5% | +$18.2K | ﹤0.01% | 4682 |
|
|
2019
Q4 | $395K | Buy |
37,858
+15,494
| +69% | +$156K | ﹤0.01% | 5065 |
|
|
2019
Q3 | $226K | Buy |
22,364
+9,891
| +79% | +$122K | ﹤0.01% | 5071 |
|
|
2019
Q2 | $143K | Buy |
12,473
+2,488
| +25% | +$47.4K | ﹤0.01% | 5171 |
|
|
2019
Q1 | $204K | Buy |
9,985
+2,298
| +30% | +$49.2K | ﹤0.01% | 5051 |
|
|
2018
Q4 | $140K | Buy |
7,687
+3,707
| +93% | +$89.4K | ﹤0.01% | 5425 |
|
|
2018
Q3 | $106K | Buy |
3,980
+1,635
| +70% | +$47.9K | ﹤0.01% | 5668 |
|
|
2018
Q2 | $70K | Sell |
2,345
-3,790
| -62% | -$116K | ﹤0.01% | 5830 |
|
|
2018
Q1 | $211K | Hold |
6,135
| – | – | ﹤0.01% | 5446 |
|
|
2017
Q4 | $265K | Sell |
6,135
-4,425
| -42% | -$221K | ﹤0.01% | 5308 |
|
|
2017
Q3 | $597K | Buy |
10,560
+7,006
| +197% | +$314K | ﹤0.01% | 4764 |
|
|
2017
Q2 | $150K | Buy |
3,554
+400
| +13% | +$15.8K | ﹤0.01% | 5472 |
|
|
2017
Q1 | $83K | Buy |
3,154
+562
| +22% | +$12.2K | ﹤0.01% | 5668 |
|
|
2016
Q4 | $46K | Buy |
2,592
+480
| +23% | +$9.12K | ﹤0.01% | 5774 |
|
|
2016
Q3 | $50K | Buy |
2,112
+295
| +16% | +$7.13K | ﹤0.01% | 5595 |
|
|
2016
Q2 | $45K | Buy |
1,817
+38
| +2% | +$1.81K | ﹤0.01% | 5566 |
|
|
2016
Q1 | $78K | Sell |
1,779
-2,949
| -62% | -$120K | ﹤0.01% | 5429 |
|
|
2015
Q4 | $258K | Buy |
4,728
+1,381
| +41% | +$60.9K | ﹤0.01% | 4948 |
|
|
2015
Q3 | $140K | Buy |
3,347
+2,847
| +569% | +$147K | ﹤0.01% | 5260 |
|
|
2015
Q2 | $26K | Buy |
+500
| New | +$26.9K | ﹤0.01% | 6067 |
|
Other funds holding CYAD
Morgan Stanley's CYAD Position: Q2 2023 in Review
Morgan Stanley sold out of Celyad Oncology SA American Depositary Shares (CYAD) in Q2 2023, closing a stake of 100 shares — an estimated $96 sold.
Morgan Stanley first reported a position in CYAD in Q2 2015 and held it in 32 quarters. The position peaked at $597K in Q3 2017. 2 funds tracked by Wall St. Rank hold CYAD as of Q2 2023.
- Morgan Stanley reported no remaining Celyad Oncology SA American Depositary Shares position as of Q2 2023 after selling out during the quarter.
- Morgan Stanley sold 100 Celyad Oncology SA American Depositary Shares shares in Q2 2023, an estimated $96.
- Morgan Stanley first reported a position in Celyad Oncology SA American Depositary Shares in Q2 2015 and held it in 32 quarters.
- Morgan Stanley's Celyad Oncology SA American Depositary Shares position peaked at $597K in Q3 2017.
- 2 funds tracked by Wall St. Rank held Celyad Oncology SA American Depositary Shares as of Q2 2023.
Based on Morgan Stanley's 13F filing for Q2 2023, filed 14 Aug 2023.